- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05230290
Clinical Study of KD6001 in Advanced Solid Tumours
February 3, 2023 updated by: Shanghai Kanda Biotechnology Co., Ltd.
Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study
The purpose of this study is to evaluate the safety, tolerability and clinical activity of KD6001 as treatment for participants with advanced solid tumours.
Study Overview
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Beijing Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Being voluntary to sign the informed consent form.
- Age ≥ 18 and ≤ 70 years at the time of signing informed consent form, male or female.
- Life expectancy of at least 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.
- Patients with histologically or cytologically confirmed advanced solid tumors: patients with advanced solid tumors who have failure in standard of care, cannot tolerate standard of care, refuse and/or have no standard of care (melanoma, renal carcinoma and urothelial carcinoma).
- Patients with at least one measurable lesion at baseline according to RECIST (Version 1.1).
- Agree to provide tumor tissue specimen (fresh biopsied sample before treatment should be provided as far as possible, the archived sample within two years is acceptable for the patients who cannot provide fresh biopsied sample before treatment).
- Adequate organ function as indicated by the laboratory results during the screening period.
- Use of highly-effective contraceptive methods during the whole study for men of reproduction ability or women of pregnant possibility (e.g. oral contraceptives, intrauterine contraceptive device or barrier contraception in combination with spermatocide), and continuation of contraception for 6 months after the end of study treatment.
- Good compliance, cooperation with follow-up.
Exclusion Criteria:
- Subjects with history of other malignant tumors within the five years prior to study entry. Except for the malignant tumors that can be expected to be cured after treatment (including treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery).
- Have been previously exposed to any anti-tumor treatment, or local anti-tumor treatment, or received investigational drug or instrument therapy.
- Having received immunotherapy within 8 weeks prior to first dose of study drug (including antibody therapy and cell therapy); Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded.
- Adverse reaction induced by previous therapy having not recovered to CTCAE (version 5.0) grade 1 or better (except alopecia and neurotoxicity, which is determined by investigators that long-term presence could not be restored).
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Having central nervous system metastases and/or cancerous meningitis.
- Subjects with previously treated brain metastases may participate.
- Having or suspected to have active autoimmune disease.
- Patients with severe hepatitis and liver cirrhosis.
- Massive hydrothorax or ascites with clinical symptoms or requiring symptomatic treatment; Having serious cardiovascular diseases, pulmonary diseases, interstitial pneumonia, chronic obstructive pulmonary disease, and symptomatic bronchospasm heart disease; Having active infection requiring systemic treatment; Positive test for HIV or AIDS; chronic active HBV or HCV; Patients with active tuberculosis.
- Systemic glucocorticoids (prednisone > 10 mg / day or other glucocorticoids of equivalent dose) and other immuno-suppressive drugs were used within 14 days before the first study drug treatment; Use of broad-spectrum antibiotics that may affect the change of intestinal flora within 14 days prior to the first dose of study drug.
- Vaccination of live vaccine within 4 weeks prior to the start of study; Having received major surgery within 4 weeks prior to the first dose of study drug; History of anti-psychotics abuse and unable to abstain, or with a history of mental disorder.
- Pregnant or breastfeeding women.
- Allergy to KD6001 or its excipients.
- Other severe, acute or chronic medical diseases or abnormalities in laboratory examination possibly increasing the relevant risk in study participation or possibly interfering the interpretation of study results as judged by the investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: KD6001 Injection
Participants will be administered KD6001 at an applicable dose as monotherapy
|
Solution for intravenous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Dose Limiting Toxicities (DLTs)
Time Frame: Up to Day 28
|
DLTs will be assessed during the dose-escalation phase and are defined as toxicities.
|
Up to Day 28
|
Incidence and nature of participants with adverse events (AEs)
Time Frame: Baseline until 30 days after last dose of KD6001
|
Evaluate the adverse events (AE) according to NCI CTCAE 5.0.
|
Baseline until 30 days after last dose of KD6001
|
To determine the Maximum tolerated dose (MTD)/Recommended Phase II dose (RP2D) of KD6001 in subjects with solid tumors
Time Frame: Baseline to study completion up to 2 years
|
If more than or equal to one third of the participants at a dose level experience dose limiting toxicity (DLT), the MTD reassessed and the next lowest dose level for the combination therapy considered the MTD.
|
Baseline to study completion up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antitumor activity measured by Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST)/Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Time Frame: Baseline to study completion up to 2 years
|
Number of participants with response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
Descriptive statistics and graphical analysis will be used to summarize patients' demographic and clinicopathological characteristics, patient safety and efficacy outcomes and correlative markers.
|
Baseline to study completion up to 2 years
|
To characterize the pharmacokinetics (PK) profile of KD6001: Maximum Observed Concentration (Cmax)
Time Frame: Baseline to study completion up to 2 years
|
Serum concentrations of KD6001 in individual subjects at different time points after KD6001 administration
|
Baseline to study completion up to 2 years
|
To evaluate the immunogenicity of KD6001: Number of subjects who develop detectable anti-drug antibodies (ADAs)
Time Frame: From baseline until 15 days after last dose of KD6001
|
The immunogenicity of KD6001 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).
|
From baseline until 15 days after last dose of KD6001
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 10, 2020
Primary Completion (ACTUAL)
July 20, 2022
Study Completion (ACTUAL)
July 26, 2022
Study Registration Dates
First Submitted
January 14, 2022
First Submitted That Met QC Criteria
January 28, 2022
First Posted (ACTUAL)
February 8, 2022
Study Record Updates
Last Update Posted (ACTUAL)
February 6, 2023
Last Update Submitted That Met QC Criteria
February 3, 2023
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KD6001CT01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
Clinical Trials on KD6001 Injection
-
Shanghai Kanda Biotechnology Co., Ltd.Recruiting
-
Shanghai Kanda Biotechnology Co., Ltd.Not yet recruitingOther Solid Tumors | Advanced HCCChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated